New Markers for Treatment Response to Radiotherapy in Prostate Cancer

NCT06159998 | Withdrawn

• 2 other identifiers: EKBB 180/09180/09
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The actual follow-up of patients undergoing definite radiotherapy for prostate cancer includes regular measurements of prostate specific antigen (PSA). Successful radiotherapy is critically dependent on local control of cancer; however, PSA takes 2-3 years to reach a nadir after therapy. We aim at collecting blood/urine after prostate massage before, and after radiotherapy in order to define new markers predicting local control earlier and more precisely than PSA.

Conditions

Prostate Cancer

Keywords

radiotherapy; markers

Outcome Measures

Primary Outcomes (1)

• Bio-repository

  first assessment using predifined markers after recruitment of 15 patients followed for 1 year

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Men undergoing definite radiotherapy for prostate cancer.

You may qualify if:

• All patients undergoing radiotherapy of biopsy confirmed clinically localised adenocarcinoma of the prostate

You may not qualify if:

• patients with inflammatory processes of the rectum
• patients with no rectum due to previous surgery

Sponsors & Collaborators

• University of Basel: lead

Study Sites (1)

Department of Urology, University Hospital Basel

Basel, Canton of Basel-City, 4031, Switzerland

Location

Biospecimen

Retention: SAMPLES WITH DNA

* PBMCs * Sera * Urine * prostate cells in urine

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Cyrill A Rentsch, MD-PhD

  University Hospital, Basel, Switzerland

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD-PhD

Study Record Dates

• First Submitted: December 11, 2012
• First Posted: December 7, 2023
• Study Start: July 1, 2009
• Primary Completion: July 1, 2014
• Study Completion: July 1, 2019
• Last Updated: December 7, 2023

Record last verified: 2023-11

Locations

CH (1)